India's customs authorities have thrown their weight behind the health ministry in a regulatory showdown with the Adani Group over nicotine pouch sales at airport duty-free outlets. The move represents a significant escalation in official pressure on billionaire Gautam Adani's sprawling business empire, with two government agencies now aligned against the conglomerate's interpretation of retail exemptions. In a court filing submitted to Mumbai's High Court on June 22, customs officials rejected the core argument underpinning Adani's legal defence—that duty-free shops operate in a zone beyond domestic regulatory controls simply because they enjoy tax advantages.
The dispute centres on nicotine pouches, a rapidly expanding global nicotine category that has gained traction among consumers but remains prohibited for sale in India. When health ministry inspectors examined Adani's flagship Mumbai international airport in March, they concluded that stocking these products violated Indian law. Rather than accept the finding, Adani has mounted a court challenge, arguing that the international departure zones where such goods are sold exist outside the jurisdiction of India's domestic regulatory framework. The company's position hinges on a technical distinction: goods destined for export-bound passengers occupy a different legal status and therefore should not fall under Indian consumer protection rules.
However, the customs department's intervention directly contradicts this reasoning. Officials stated plainly that tax and customs privileges do not confer immunity from other regulations that the Indian state wishes to enforce. "The concept of goods being 'outside customs frontiers' for taxation purposes does not grant immunity from regulatory controls," the department declared in its formal submission to the court. This language cuts to the heart of the matter: Adani has attempted to exploit a technical loophole in tax law to circumvent health restrictions. The customs authority's rejection of this interpretation means the company faces regulatory pressure on multiple fronts simultaneously, complicating any defence strategy.
Adani's counter-argument, presented in a July 13 filing, rests on procedural grounds in addition to jurisdictional claims. The company contends that customs officials should have issued a formal warning notice before demanding the suspension of sales, and that the absence of such notice invalidates their enforcement action. Moreover, Adani emphasises that nicotine pouches purchased at duty-free shops must be placed in sealed bags and theoretically remain unused until passengers clear Indian airspace. Under this interpretation, the sale itself is not truly within India's jurisdiction because the product is destined for consumption abroad. The argument reveals Adani's attempt to construct a legal firewall between the act of selling and the act of consuming.
Yet this reasoning appears vulnerable to the commonsense observation that the customs department has now highlighted in court filings. Once passengers take possession of duty-free goods—whether in sealed bags or otherwise—they retain the freedom to open and use those items at any point, including while still on Indian territory or even after returning home. The company cannot realistically police the downstream behaviour of purchasers, nor can it credibly maintain that sale within India with full knowledge of buyer intent differs meaningfully from facilitating consumption. This logical gap in Adani's defence helps explain why customs decided to join the health ministry's case rather than remaining neutral.
The commercial stakes driving this dispute are substantial. Nicotine pouches represent one of the world's fastest-growing segments within the broader nicotine market, with Western manufacturers reporting explosive growth. Philip Morris International, the maker of the Zyn brand that Adani has been stocking, reported that US sales doubled between 2023 and the following year, signalling massive consumer appetite in developed markets. Sweden's Smokeless Solutions, which manufactures both Zyn and White Fox brands, has supplied Adani with over $35,000 worth of inventory since August, suggesting genuine commercial ambition rather than incidental retail activity.
For Adani, the financial implications extend well beyond nicotine pouch margins. The billionaire's airport portfolio comprises eight facilities across India, and he is pursuing an ambitious US$11 billion expansion programme that relies heavily on duty-free retail revenue as a driver of profitability. Duty-free shopping represents a high-margin business segment that significantly enhances overall airport economics. A regulatory loss in this case could establish a precedent whereby other unapproved products face similar challenges, potentially constraining the commercial flexibility that Adani was counting on in his expansion calculations. The dispute thus touches on fundamental questions about how Indian regulatory bodies will approach the gatekeeping function at increasingly commercialised airport retail environments.
For Southeast Asian readers, the case carries broader implications about how regional governments may treat emerging nicotine products and the extent to which retailers can exploit tax exemptions as regulatory workarounds. Several neighbouring countries have adopted cautious or prohibitive stances toward nicotine pouches, viewing them as products that circumvent traditional tobacco regulations. If Adani's defence fails—and the customs intervention suggests it likely will—the precedent could encourage regulatory agencies across the region to scrutinise duty-free retailers more closely. This may limit international retailers' ability to use airport zones as channels for products banned or restricted in domestic markets.
The case will return to court on July 28 for further hearing, at which point the judges must grapple with the tension between tax law and health law that Adani's business model has exposed. The company clearly anticipated that the duty-free framework would insulate it from regulatory challenge, but the government's coordinated response suggests Indian authorities regard this as an attempt to evade substantive public health policy. Neither Adani nor government officials responded to media inquiries about the specifics of their positions, leaving the legal arguments to speak for themselves in court filings. The outcome will likely shape how Indian airports approach the retail of controversial or unapproved products for years to come.
